<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02434380</url>
  </required_header>
  <id_info>
    <org_study_id>AUBMC-GE-HF-2</org_study_id>
    <secondary_id>AUBMC-IM-GE-HF-22</secondary_id>
    <nct_id>NCT02434380</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin D Replacement on Maternal and Neonatal Outcomes</brief_title>
  <official_title>Effect of Vitamin D Replacement on Maternal and Neonatal Outcomes: a Randomized Controlled Trial in Pregnant Women With Hypovitaminosis D</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American University of Beirut Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Southampton</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bahman Hospital Beirut Lebanon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>American University of Beirut Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The optimal vitamin D replacement dose during pregnancy remains undefined. Therefore, the aim
      of this study is to test the hypothesis that a daily equivalent dose of vitamin D of 3,000
      IU/day is needed for Middle Eastern women, to optimize maternal vitamin D level and neonatal
      musculoskeletal parameters, specifically knee-heel length at birth and bone mineral content
      at one month of age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypovitaminosis D is prevalent worldwide across the lifecycle, including pregnant women, and
      particularly in the Middle East. It has been associated with adverse maternal and neonatal
      outcomes. While the Institute of Medicine (IOM) recommends 600 IU of vitamin D per day to
      reach a 25-Hydroxyvitamin D (25(OH)D) level ≥ 20 ng/ml, the Endocrine Society (ES) recommends
      1,500-2,000 IU/day to reach a level ≥ 30 ng/ml, and the WHO guidelines do not recommend any
      supplementation as part of routine prenatal care. They do however underscore the fact that
      subjects with the lowest levels may be the ones to benefit most from vitamin D replacement.
      The benefits of such an approach and the doses needed to reach desirable levels have not been
      tested. This randomized trial proposes to do so, testing the effect of two vitamin D doses, a
      low dose of 600 IU daily and a high dose of 3,000 IU daily.

      330 pregnant women, with 25(OH)D level 10-30 ng/ml during the early second trimester will be
      recruited form the American University of Beirut-Medical Center (AUB-MC), and Bahman
      Hospital. They will be randomized, in a double blinded fashion, to receive daily equivalent
      doses of cholecalciferol, 600 IU or 3,000 IU until delivery. Maternal clinical information
      and a food frequency questionnaire will be obtained at each visit until delivery. Maternal
      25(OH)D and chemistries, including Calcium, creatinine, lipid profile, glucose and Insulin
      will be assessed at study entry, during third trimester and at delivery. Fetal measurements
      will be collected at study entry and during the second trimester. Neonatal anthropometric
      variables and venous umbilical cord 25(OH)D level will be measured at birth and infants will
      also undergo dual-energy x-ray absorptiometry (DEXA) scan assessment, for bone and fat mass,
      at one to 6 weeks. Maternal and neonatal genetic studies for vitamin D genes polymorphism,
      and other modules of placnetal calcium transport will be also performed.

      Throughout the study, adverse events will be collected systematically and an independent Data
      and Safety Monitoring Board will be asked to review serious adverse events.

      The percent of women achieving 25(OH)D ≥ 20ng/ml in the low dose will be compared to that in
      the high dose using Chi-Square. Independent t-test will be used to compare mean neonatal bone
      mineral content at one month of age between the 2 arms. For other outcomes, t-test will be
      used for continuous outcomes and Chi-square will be used for binary outcomes to compare means
      and proportions, respectively. The primary analysis is an intention-to-treat analysis (ITT)
      of unadjusted results. For the primary outcomes, p- values will be considered statistically
      significant if ≤ 0.025.

      The investigators study would be the only randomized controlled trial in the Middle East, to
      investigate the recommended daily allowance for vitamin D, and the desirable dose to optimize
      neonatal musculoskeletal health, in women with low 25(OH)D levels, levels that are reflective
      of those in most countries from the Middle East.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportions of women who will reach the IOM defined desirable 25(OH)D level ≥20ng/ml.</measure>
    <time_frame>At delivery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Infant bone mineral content (BMC)</measure>
    <time_frame>one to six weeks</time_frame>
    <description>We will assess Infant bone mineral content (BMC) by whole body dual-energy x-ray absorptiometry (DEXA) scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal 25(OH)D level</measure>
    <time_frame>At delivery</time_frame>
    <description>We will assess mean maternal 25(OH)D level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal 25(OH)D level, at delivery</measure>
    <time_frame>At birth</time_frame>
    <description>We will assess mean neonatal 25(OH)D level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean infant fat mass</measure>
    <time_frame>At one month of age</time_frame>
    <description>We will assess Infant fat mass by whole body dual-energy x-ray absorptiometry (DEXA) scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Knee to heel length at birth</measure>
    <time_frame>At birth</time_frame>
    <description>We will assess neonatal Knee to heel length at birth using simple vernier calipers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Parathyroid Hormone (PTH) Level</measure>
    <time_frame>At delivery</time_frame>
    <description>We will assess mean maternal PTH level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Parathyroid Hormone (PTH) Level</measure>
    <time_frame>At birth</time_frame>
    <description>We will assess mean neonatal PTH level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in maternal urine calcium</measure>
    <time_frame>Change between baseline and 3 months following intervention</time_frame>
    <description>We will assess the change in urine calcium level after 3 months of vitamin D supplementation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Composite outcome (incidence of C-section and gestational diabetes mellitus (GDM))</measure>
    <time_frame>At delivery</time_frame>
    <description>We will assess the incidence of a composite outcome (C-section and gestational diabetes mellitus (GDM)) in a subgroup of women who has no previous C-section.</description>
  </other_outcome>
  <other_outcome>
    <measure>Maternal weight</measure>
    <time_frame>At delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Maternal Blood Pressure (BP)</measure>
    <time_frame>At delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of ill days</measure>
    <time_frame>At 28-32 weeks Gestational Age (GA) and at delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Intrauterine fetal skeletal measures</measure>
    <time_frame>At 11-13 weeks and at 20 weeks</time_frame>
    <description>We will collect intrauterine fetal skeletal measures including crown-rump, femur length, abdominal circumference, head circumference, biparietal diameter</description>
  </other_outcome>
  <other_outcome>
    <measure>APGAR score</measure>
    <time_frame>At delivery</time_frame>
    <description>Proportion of neonates with low APGAR (&lt;7) score at 1 and 5 minutes, at delivery</description>
  </other_outcome>
  <other_outcome>
    <measure>Neonatal weight</measure>
    <time_frame>At birth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Neonatal length</measure>
    <time_frame>At birth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Placental weight</measure>
    <time_frame>At delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Placental 1α hydroxylase activity</measure>
    <time_frame>At delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Sub-group analysis: The proportions of women who will reach the IOM defined desirable 25(OH)D level ≥20ng/ml.</measure>
    <time_frame>At delivery</time_frame>
    <description>Subgroup analysis based on baseline 25(OH)D, less than 20 ng/ml versus less than 30 ng/ml and season of birth will be performed</description>
  </other_outcome>
  <other_outcome>
    <measure>Sub-group analysis:Infant bone mineral content (BMC)</measure>
    <time_frame>One month of age</time_frame>
    <description>Subgroup analysis based on baseline 25(OH)D, less than 20 ng/ml versus less than 30 ng/ml and season of birth will be performed.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Hypovitaminosis D</condition>
  <condition>Pregnancy Complications</condition>
  <condition>Infant, Newborn, Diseases</condition>
  <arm_group>
    <arm_group_label>Low dose vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D3 Euro D 10,000 IU (1 tablet) plus Euro D Placebo (1 tablet) weekly, alternating with Euro D Placebo (2 tablets) weekly, starting at the second trimester and continued until delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D3 Euro D 10,000 IU (2 tablets, equivalent to 20,000 IU) weekly, starting at the second trimester and continued until delivery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Euro D</intervention_name>
    <description>Vitamin D3 Euro D 10,000 IU (1 tablet) plus Euro D Placebo (1 tablet) weekly, alternating with Euro D Placebo (2 tablets) weekly, starting at the second trimester and continued until delivery.</description>
    <arm_group_label>Low dose vitamin D</arm_group_label>
    <other_name>Europharm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Euro D</intervention_name>
    <description>Vitamin D3 Euro D 10,000 IU (2 tablets, equivalent to 20,000 IU) weekly, starting at the second trimester and continued until delivery.</description>
    <arm_group_label>High dose vitamin D</arm_group_label>
    <other_name>Europharm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women gestational age (GA)&lt; 14 weeks at screening visit. Middle Eastern woman
             (Middle East countries defined by WHO: Bahrain, Egypt, Iran, Iraq, Palestine, Jordan,
             Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Syria, , United Arab Emirates, Yemen)

          -  25(OH)D level between 10ng/ml and 30ng/ml

          -  Age &gt; 18 years

          -  Vitamin D supplementation ≤ 200 IU daily (If daily vitamin D supplementation &gt; 200 IU
             daily, at enrollment, the pregnant women will be advised to adjust prenatal
             multivitamin doses in such a way that total vitamin D supplementation per week doesn't
             exceed 1400 IU per week, in consultation with primary Obstetric and Gynecology
             (OB-GYN) physician.)

        Exclusion Criteria:

          -  25(OH)D level &lt; 10 ng/ml or &gt; 30 ng/ml.

          -  Known metabolic bone disease

          -  Current medications likely to interfere with vitamin D metabolism (enzyme inducing
             anticonvulsants, anti -TB)

          -  Vitamin D supplementation &gt; 600 IU daily

          -  Pregnant women with twins
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ghada El Hajj Fuleihan, Professor of Medicine</last_name>
    <role>Principal Investigator</role>
    <affiliation>American University of Beirut Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ghada El Hajj Fuleihan, Professor of Medicine</last_name>
    <email>gf01@aub.edu.lb</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anwar Nassar, Professor; Co-Investigator</last_name>
    <email>an21@aub.edu.lb</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>American University of Beirut</name>
      <address>
        <city>Hamra</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghada El hajj Fuleihan, Professor of Medicine</last_name>
      <phone>961-1-737868</phone>
      <email>gf01@aub.edu.lb</email>
    </contact>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <reference>
    <citation>Kovacs CS, Fuleihan Gel-H. Calcium and bone disorders during pregnancy and lactation. Endocrinol Metab Clin North Am. 2006 Mar;35(1):21-51, v. Review.</citation>
    <PMID>16310641</PMID>
  </reference>
  <reference>
    <citation>Bassil D, Rahme M, Hoteit M, Fuleihan Gel-H. Hypovitaminosis D in the Middle East and North Africa: Prevalence, risk factors and impact on outcomes. Dermatoendocrinol. 2013 Apr 1;5(2):274-98. doi: 10.4161/derm.25111.</citation>
    <PMID>24194968</PMID>
  </reference>
  <reference>
    <citation>Arabi A, El Rassi R, El-Hajj Fuleihan G. Hypovitaminosis D in developing countries-prevalence, risk factors and outcomes. Nat Rev Endocrinol. 2010 Oct;6(10):550-61. doi: 10.1038/nrendo.2010.146. Review.</citation>
    <PMID>20852586</PMID>
  </reference>
  <reference>
    <citation>Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA, El-Hajj Fuleihan G, Josse RG, Lips P, Morales-Torres J; IOF Committee of Scientific Advisors (CSA) Nutrition Working Group. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int. 2009 Nov;20(11):1807-20. doi: 10.1007/s00198-009-0954-6. Epub 2009 Jun 19. Review. Erratum in: Osteoporos Int. 2009 Nov;20(11):1821.</citation>
    <PMID>19543765</PMID>
  </reference>
  <reference>
    <citation>Hoteit M, Al-Shaar L, Yazbeck C, Bou Sleiman M, Ghalayini T, Fuleihan Gel-H. Hypovitaminosis D in a sunny country: time trends, predictors, and implications for practice guidelines. Metabolism. 2014 Jul;63(7):968-78. doi: 10.1016/j.metabol.2014.04.009. Epub 2014 Apr 23.</citation>
    <PMID>24874590</PMID>
  </reference>
  <reference>
    <citation>El-Hajj Fuleihan G, Nabulsi M, Tamim H, Maalouf J, Salamoun M, Khalife H, Choucair M, Arabi A, Vieth R. Effect of vitamin D replacement on musculoskeletal parameters in school children: a randomized controlled trial. J Clin Endocrinol Metab. 2006 Feb;91(2):405-12. Epub 2005 Nov 8.</citation>
    <PMID>16278262</PMID>
  </reference>
  <reference>
    <citation>Morley R, Carlin JB, Pasco JA, Wark JD. Maternal 25-hydroxyvitamin D and parathyroid hormone concentrations and offspring birth size. J Clin Endocrinol Metab. 2006 Mar;91(3):906-12. Epub 2005 Dec 13.</citation>
    <PMID>16352684</PMID>
  </reference>
  <reference>
    <citation>Al-Shaar L, Mneimneh R, Nabulsi, Maalouf J, Fuleihan Gel-H. Vitamin D3 dose requirement to raise 25-hydroxyvitamin D to desirable levels in adolescents: results from a randomized controlled trial. J Bone Miner Res. 2014 Apr;29(4):944-51. doi: 10.1002/jbmr.2111.</citation>
    <PMID>24123134</PMID>
  </reference>
  <reference>
    <citation>Parkes I, Schenker JG, Shufaro Y. Parathyroid and calcium metabolism disorders during pregnancy. Gynecol Endocrinol. 2013 Jun;29(6):515-9. doi: 10.3109/09513590.2012.754880. Epub 2013 Jan 25. Review.</citation>
    <PMID>23350730</PMID>
  </reference>
  <reference>
    <citation>Nassar N, Halligan GH, Roberts CL, Morris JM, Ashton AW. Systematic review of first-trimester vitamin D normative levels and outcomes of pregnancy. Am J Obstet Gynecol. 2011 Sep;205(3):208.e1-7. doi: 10.1016/j.ajog.2011.03.058. Epub 2011 Apr 7. Review.</citation>
    <PMID>21640968</PMID>
  </reference>
  <reference>
    <citation>Hollis BW, Wagner CL. Vitamin D and pregnancy: skeletal effects, nonskeletal effects, and birth outcomes. Calcif Tissue Int. 2013 Feb;92(2):128-39. doi: 10.1007/s00223-012-9607-4. Epub 2012 May 24. Review.</citation>
    <PMID>22623177</PMID>
  </reference>
  <reference>
    <citation>Thorne-Lyman A, Fawzi WW. Vitamin D during pregnancy and maternal, neonatal and infant health outcomes: a systematic review and meta-analysis. Paediatr Perinat Epidemiol. 2012 Jul;26 Suppl 1:75-90. doi: 10.1111/j.1365-3016.2012.01283.x. Review.</citation>
    <PMID>22742603</PMID>
  </reference>
  <reference>
    <citation>Harvey NC, Moon RJ, Sayer AA, Ntani G, Davies JH, Javaid MK, Robinson SM, Godfrey KM, Inskip HM, Cooper C; Southampton Women's Survey Study Group. Maternal antenatal vitamin D status and offspring muscle development: findings from the Southampton Women's Survey. J Clin Endocrinol Metab. 2014 Jan;99(1):330-7. doi: 10.1210/jc.2013-3241. Epub 2013 Dec 20.</citation>
    <PMID>24178796</PMID>
  </reference>
  <reference>
    <citation>Javaid MK, Crozier SR, Harvey NC, Gale CR, Dennison EM, Boucher BJ, Arden NK, Godfrey KM, Cooper C; Princess Anne Hospital Study Group. Maternal vitamin D status during pregnancy and childhood bone mass at age 9 years: a longitudinal study. Lancet. 2006 Jan 7;367(9504):36-43. Erratum in: Lancet. 2006 May 6;367(9521):1486.</citation>
    <PMID>16399151</PMID>
  </reference>
  <reference>
    <citation>Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011 Jan;96(1):53-8. doi: 10.1210/jc.2010-2704. Epub 2010 Nov 29.</citation>
    <PMID>21118827</PMID>
  </reference>
  <reference>
    <citation>Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30. doi: 10.1210/jc.2011-0385. Epub 2011 Jun 6. Erratum in: J Clin Endocrinol Metab. 2011 Dec;96(12):3908.</citation>
    <PMID>21646368</PMID>
  </reference>
  <reference>
    <citation>Harvey N, Dennison E, Cooper C. Osteoporosis: a lifecourse approach. J Bone Miner Res. 2014 Sep;29(9):1917-25. doi: 10.1002/jbmr.2286. Review.</citation>
    <PMID>24861883</PMID>
  </reference>
  <reference>
    <citation>De-Regil LM, Palacios C, Ansary A, Kulier R, Peña-Rosas JP. Vitamin D supplementation for women during pregnancy. Cochrane Database Syst Rev. 2012 Feb 15;(2):CD008873. doi: 10.1002/14651858.CD008873.pub2. Review. Update in: Cochrane Database Syst Rev. 2016;(1):CD008873.</citation>
    <PMID>22336854</PMID>
  </reference>
  <reference>
    <citation>Hollis BW, Johnson D, Hulsey TC, Ebeling M, Wagner CL. Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness. J Bone Miner Res. 2011 Oct;26(10):2341-57. doi: 10.1002/jbmr.463. Erratum in: J Bone Miner Res. 2011 Dec; 26(12):3001.</citation>
    <PMID>21706518</PMID>
  </reference>
  <reference>
    <citation>Dawodu A, Saadi HF, Bekdache G, Javed Y, Altaye M, Hollis BW. Randomized controlled trial (RCT) of vitamin D supplementation in pregnancy in a population with endemic vitamin D deficiency. J Clin Endocrinol Metab. 2013 Jun;98(6):2337-46. doi: 10.1210/jc.2013-1154. Epub 2013 Apr 4.</citation>
    <PMID>23559082</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2015</study_first_submitted>
  <study_first_submitted_qc>May 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2015</study_first_posted>
  <last_update_submitted>January 15, 2018</last_update_submitted>
  <last_update_submitted_qc>January 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>American University of Beirut Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Ghada El-Hajj Fuleihan</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Bone mineral content</keyword>
  <keyword>Knee-heel length</keyword>
  <keyword>Middle East</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnancy Complications</mesh_term>
    <mesh_term>Avitaminosis</mesh_term>
    <mesh_term>Rickets</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Infant, Newborn, Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

